With plans to bring su­r­u­fa­tinib state­side, Chi-Med vast­ly scales up man­u­fac­tur­ing with new Chi­nese plant

Hutchi­son Chi­na MediTech, or Chi-Med, is at­tempt­ing to break new ground by bring­ing its in­ter­nal­ly de­vel­oped on­col­o­gy can­di­date su­r­u­fa­tinib to US shores—which would make it just the sec­ond Chi­nese-de­vel­oped drug to do so. With that goal in mind, the firm is vast­ly scal­ing up its man­u­fac­tur­ing op­er­a­tions for a planned glob­al push.

Chi-Med is build­ing out a new large-scale man­u­fac­tur­ing fa­cil­i­ty in Zhangjiang, Shang­hai, that will to­tal 592,000 square feet of floor space and boost the com­pa­ny’s pro­duc­tion ca­pac­i­ty by more than 600% past its cur­rent op­er­a­tions in Suzhou.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.